RxDoctor Payments Data

David Wilson, MD

Internal Medicine · Oklahoma City, OKNPI 1740377027

Payments from drug & device makers

$425in general payments, 2019–2025

Across 28 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$122
  • GSK$101
  • Pfizer$84
  • E.r. Squibb & Sons, L.L.C.$27
  • Abbott$19
  • Dexcom, Inc.$15
  • plus $57 from 5 others

What the payments were for

  • Food & beverage$425100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$425 in reported general payments places this provider in the 55th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$205,865
Medicare patients
643
Services billed
4,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab12$148,952
EliquisApixaban127$127,423
JanuviaSitagliptin Phosphate64$105,890
OzempicSemaglutide69$83,857
MounjaroTirzepatide60$63,065
JardianceEmpagliflozin33$60,851
TriumeqAbacavir/Dolutegravir/Lamivudi12$40,723
MyrbetriqMirabegron35$34,356
TrulicityDulaglutide26$31,049
Tresiba Flextouch U-100Insulin Degludec23$16,234
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$14,858
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$14,430
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,514
LinzessLinaclotide15$10,353
Breo ElliptaFluticasone/Vilanterol12$10,245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$84$135,813143 claims
MerckJanuvia$14$105,89064 claims
Lilly USA, LLCMounjaro, Trulicity$12$94,11486 claims
Astellas Pharma US IncMyrbetriq$13$34,35635 claims
GSKTrelegy Ellipta, Breo Ellipta$101$20,75925 claims
AbbVieLinzess, Synthroid$122$15,83978 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →